On-Demand Webinar: Manage growing literature review workloads with pharmacovigilance automation and integration
April 15, 2021
Literature review teams in drug safety departments are overloaded with a rising tide of work and decreasing budgets. The number of adverse events being reported is growing year on year, along with the amount of literature that needs to be monitored. For drug safety teams, this pace isn’t sustainable; they either need to employ more reviewers or run the risk of valid ICSRs being missed by overworked teams.
However, this problem can be exacerbated by the way the literature review process is carried out. Too many literature review processes get bogged down in the quicksand of spreadsheets or other inefficient solutions. Using unvalidated, manual processes to track literature results in inefficiencies and increased risk.
In fact, it is only through pharmacovigilance automation and integration that drug safety departments can ever hope to tackle the rising case load without drastically increasing the size (and cost) of their teams. Automation and integration can introduce a level of efficiency that you can’t get by just using a bigger review team.
That’s why we’ve developed this on-demand webinar taking a closer look at these issues and what drug safety teams can do to address them. In this webinar you’ll learn more about:
- The unavoidable challenge pharmaceuticals face from a growing literature review workload
- Why this workload is unsustainable
- What pharmacovigilance automation can do to streamline the literature review workload without adding risk
- How integration with downstream systems can improve the whole pharmacovigilance workflow
- How drug safety departments can prepare for the future of literature monitoring for product safety
To watch the webinar, all you need to do is fill out your details in the form below. You’ll then receive an email from Livestorm.co – you just need to click the button in the email to watch the webinar:
Register for the webinar:
The question many Market Authorisation Holders (MAH) are asking themselves at the moment is how...
Drug safety literature screening for patient safety issues is not easy an easy process. As we saw...
If it isn’t documented, it doesn’t exist. As far as regulators are concerned, this is true for any...